Skip to main content
Erschienen in: Cellular Oncology 4/2012

01.08.2012 | Original Paper

Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection

verfasst von: Linda J. W. Bosch, Sandra Mongera, Jochim S. Terhaar sive Droste, Frank A. Oort, Sietze T. van Turenhout, Maarten T. Penning, Joost Louwagie, Chris J. J. Mulder, Manon van Engeland, Beatriz Carvalho, Gerrit A. Meijer

Erschienen in: Cellular Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Stool-based molecular tests hold large potential for improving colorectal cancer screening. Here, we investigated the analytical sensitivity of a DNA methylation assay on partial stool samples, and estimated the DNA degradation in stool over time. In addition, we explored the detection of DNA methylation in fecal immunochemical test (FIT) fluid.

Materials and Methods

Partial stool samples of colonoscopy-negative individuals were homogenized with stool homogenization buffer, spiked with different numbers of HCT116 colon cancer cells and kept at room temperature for 0, 24, 48, 72 and 144 h before DNA isolation. Analytical sensitivity was determined by the lowest number of cells that yielded positive test results by DNA methylation or mutation analysis. DNA methylation in FIT fluid was measured in 11 CRC patients and 20 control subjects.

Results

The analytical sensitivity for detecting DNA methylation was 3000 cells per gram stool, compared to 60000 cells per gram stool for detection of DNA mutations in the same stool samples. No degradation up to 72 h was noted when a conservation buffer was used. DNA methylation was detected in 4/11 CRC FIT samples and in none of the 20 control FIT samples.

Conclusions

Methylation based stool DNA testing showed a high analytical sensitivity for tumor DNA in partial stool samples, which was hardly influenced by DNA degradation over time, provided an adequate buffer was used. The feasibility of detecting DNA methylation in FIT fluid demonstrates the opportunity to combine testing for occult blood with DNA methylation in the same collection device.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat J.E. Allison, M. Lawson, Screening tests for colorectal cancer: a menu of options remains relevant. Curr. Oncol. Rep. 8, 492–498 (2006)PubMedCrossRef J.E. Allison, M. Lawson, Screening tests for colorectal cancer: a menu of options remains relevant. Curr. Oncol. Rep. 8, 492–498 (2006)PubMedCrossRef
2.
Zurück zum Zitat G. Hoff, J.A. Dominitz, Contrasting US and European approaches to colorectal cancer screening: which is best? Gut 59, 407–414 (2010)PubMedCrossRef G. Hoff, J.A. Dominitz, Contrasting US and European approaches to colorectal cancer screening: which is best? Gut 59, 407–414 (2010)PubMedCrossRef
3.
Zurück zum Zitat D.R. Wang, D. Tang, Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 14, 524–531 (2008)PubMedCrossRef D.R. Wang, D. Tang, Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 14, 524–531 (2008)PubMedCrossRef
4.
Zurück zum Zitat S.C. Glockner, M. Dhir, J.M. Yi, K.E. McGarvey, N.L. Van, J. Louwagie, T.A. Chan, W. Kleeberger, A.P. de Bruine, K.M. Smits, C.A. Khalid-de Bakker, D.M. Jonkers, R.W. Stockbrugger, G.A. Meijer, F.A. Oort, C. Iacobuzio-Donahue, K. Bierau, J.G. Herman, S.B. Baylin, E.M. Van, K.E. Schuebel, N. Ahuja, Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69, 4691–4699 (2009)PubMedCrossRef S.C. Glockner, M. Dhir, J.M. Yi, K.E. McGarvey, N.L. Van, J. Louwagie, T.A. Chan, W. Kleeberger, A.P. de Bruine, K.M. Smits, C.A. Khalid-de Bakker, D.M. Jonkers, R.W. Stockbrugger, G.A. Meijer, F.A. Oort, C. Iacobuzio-Donahue, K. Bierau, J.G. Herman, S.B. Baylin, E.M. Van, K.E. Schuebel, N. Ahuja, Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69, 4691–4699 (2009)PubMedCrossRef
5.
Zurück zum Zitat V. Melotte, M.H. Lentjes, S.M. van den Bosch, D.M. Hellebrekers, J.P. de Hoon, K.A. Wouters, K.L. Daenen, I.E. Partouns-Hendriks, F. Stessels, J. Louwagie, K.M. Smits, M.P. Weijenberg, S. Sanduleanu, C.A. Khalid-de Bakker, F.A. Oort, G.A. Meijer, D.M. Jonkers, J.G. Herman, A.P. de Bruine, E.M. Van, N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101, 916–927 (2009)PubMedCrossRef V. Melotte, M.H. Lentjes, S.M. van den Bosch, D.M. Hellebrekers, J.P. de Hoon, K.A. Wouters, K.L. Daenen, I.E. Partouns-Hendriks, F. Stessels, J. Louwagie, K.M. Smits, M.P. Weijenberg, S. Sanduleanu, C.A. Khalid-de Bakker, F.A. Oort, G.A. Meijer, D.M. Jonkers, J.G. Herman, A.P. de Bruine, E.M. Van, N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101, 916–927 (2009)PubMedCrossRef
6.
Zurück zum Zitat L.J. Bosch, F.A. Oort, M. Neerincx, C.A. Khalid-de Bakker, J.S. Terhaar Sive Droste, V. Melotte, D.M. Jonkers, A.A. Masclee, S. Mongera, M. Grooteclaes, J. Louwagie, C.W. Van, V.M. Coupe, C.J. Mulder, E.M. Van, B. Carvalho, G.A. Meijer, DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res Phila 5, 464–472 (2012)PubMedCrossRef L.J. Bosch, F.A. Oort, M. Neerincx, C.A. Khalid-de Bakker, J.S. Terhaar Sive Droste, V. Melotte, D.M. Jonkers, A.A. Masclee, S. Mongera, M. Grooteclaes, J. Louwagie, C.W. Van, V.M. Coupe, C.J. Mulder, E.M. Van, B. Carvalho, G.A. Meijer, DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res Phila 5, 464–472 (2012)PubMedCrossRef
7.
Zurück zum Zitat Y.X. Luo, D.K. Chen, S.X. Song, L. Wang, J.P. Wang, Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int. J. Clin. Pract. 65, 1313–1320 (2011)PubMedCrossRef Y.X. Luo, D.K. Chen, S.X. Song, L. Wang, J.P. Wang, Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int. J. Clin. Pract. 65, 1313–1320 (2011)PubMedCrossRef
8.
Zurück zum Zitat L.J. Bosch, B. Carvalho, R.J. Fijneman, C.R. Jimenez, H.M. Pinedo, E.M. Van, G.A. Meijer, Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10, 8–23 (2011)PubMed L.J. Bosch, B. Carvalho, R.J. Fijneman, C.R. Jimenez, H.M. Pinedo, E.M. Van, G.A. Meijer, Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10, 8–23 (2011)PubMed
9.
Zurück zum Zitat J. Olson, D.H. Whitney, K. Durkee, A.P. Shuber, DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn. Mol. Pathol. 14, 183–191 (2005)PubMedCrossRef J. Olson, D.H. Whitney, K. Durkee, A.P. Shuber, DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn. Mol. Pathol. 14, 183–191 (2005)PubMedCrossRef
10.
Zurück zum Zitat F.A. Oort, J.S. Droste, R.W. Van Der Hulst, H.A. Van Heukelem, R.J. Loffeld, I.C. Wesdorp, R.L. Van Wanrooij, B.L. De, E.R. Mutsaers, R.S. Van Der, V.M. Coupe, J. Berkhof, A.A. Bouman, G.A. Meijer, C.J. Mulder, Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment. Pharmacol. Ther. 31, 432–439 (2010)PubMedCrossRef F.A. Oort, J.S. Droste, R.W. Van Der Hulst, H.A. Van Heukelem, R.J. Loffeld, I.C. Wesdorp, R.L. Van Wanrooij, B.L. De, E.R. Mutsaers, R.S. Van Der, V.M. Coupe, J. Berkhof, A.A. Bouman, G.A. Meijer, C.J. Mulder, Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment. Pharmacol. Ther. 31, 432–439 (2010)PubMedCrossRef
11.
Zurück zum Zitat T.E. Buffart, M. Tijssen, T. Krugers, B. Carvalho, S.J. Smeets, R.H. Brakenhoff, H. Grabsch, G.A. Meijer, H.B. Sadowski, B. Ylstra, DNA quality assessment for array CGH by isothermal whole genome amplification. Cell. Oncol. 29, 351–359 (2007)PubMed T.E. Buffart, M. Tijssen, T. Krugers, B. Carvalho, S.J. Smeets, R.H. Brakenhoff, H. Grabsch, G.A. Meijer, H.B. Sadowski, B. Ylstra, DNA quality assessment for array CGH by isothermal whole genome amplification. Cell. Oncol. 29, 351–359 (2007)PubMed
12.
Zurück zum Zitat M.L. Janmaat, J.A. Rodriguez, M. Gallegos-Ruiz, F.A. Kruyt, G. Giaccone, Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 118, 209–214 (2006)PubMedCrossRef M.L. Janmaat, J.A. Rodriguez, M. Gallegos-Ruiz, F.A. Kruyt, G. Giaccone, Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 118, 209–214 (2006)PubMedCrossRef
13.
Zurück zum Zitat M.I. Gallegos Ruiz, K. Floor, F. Rijmen, K. Grunberg, J.A. Rodriguez, G. Giaccone, EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell. Oncol. 29, 257–264 (2007)PubMed M.I. Gallegos Ruiz, K. Floor, F. Rijmen, K. Grunberg, J.A. Rodriguez, G. Giaccone, EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell. Oncol. 29, 257–264 (2007)PubMed
14.
Zurück zum Zitat J.C. Brandes, E.M. Van, K.A. Wouters, M.P. Weijenberg, J.G. Herman, CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26, 1152–1156 (2005)PubMedCrossRef J.C. Brandes, E.M. Van, K.A. Wouters, M.P. Weijenberg, J.G. Herman, CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26, 1152–1156 (2005)PubMedCrossRef
15.
Zurück zum Zitat Z. Levi, P. Rozen, R. Hazazi, A. Vilkin, A. Waked, E. Maoz, S. Birkenfeld, M. Leshno, Y. Niv, A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann. Intern. Med. 146, 244–255 (2007)PubMed Z. Levi, P. Rozen, R. Hazazi, A. Vilkin, A. Waked, E. Maoz, S. Birkenfeld, M. Leshno, Y. Niv, A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann. Intern. Med. 146, 244–255 (2007)PubMed
16.
Zurück zum Zitat D.A. Ahlquist, D.J. Sargent, C.L. Loprinzi, T.R. Levin, D.K. Rex, D.J. Ahnen, K. Knigge, M.P. Lance, L.J. Burgart, S.R. Hamilton, J.E. Allison, M.J. Lawson, M.E. Devens, J.J. Harrington, S.L. Hillman, Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149, 441–50 (2008). W81PubMed D.A. Ahlquist, D.J. Sargent, C.L. Loprinzi, T.R. Levin, D.K. Rex, D.J. Ahnen, K. Knigge, M.P. Lance, L.J. Burgart, S.R. Hamilton, J.E. Allison, M.J. Lawson, M.E. Devens, J.J. Harrington, S.L. Hillman, Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149, 441–50 (2008). W81PubMed
17.
Zurück zum Zitat T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, B.A. Turnbull, M.E. Ross, Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351, 2704–2714 (2004)PubMedCrossRef T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, B.A. Turnbull, M.E. Ross, Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351, 2704–2714 (2004)PubMedCrossRef
18.
Zurück zum Zitat S. Itzkowitz, R. Brand, L. Jandorf, K. Durkee, J. Millholland, L. Rabeneck, P.C. Schroy, III, S. Sontag, D. Johnson, S. Markowitz, L. Paszat, and B.M. Berger, A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection. Am. J. Gastroenterol. 103, 2862–2870 (2008) S. Itzkowitz, R. Brand, L. Jandorf, K. Durkee, J. Millholland, L. Rabeneck, P.C. Schroy, III, S. Sontag, D. Johnson, S. Markowitz, L. Paszat, and B.M. Berger, A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection. Am. J. Gastroenterol. 103, 2862–2870 (2008)
19.
Zurück zum Zitat D.M. Hellebrekers, M.H. Lentjes, S.M. van den Bosch, V. Melotte, K.A. Wouters, K.L. Daenen, K.M. Smits, Y. Akiyama, Y. Yuasa, S. Sanduleanu, C.A. Khalid-de Bakker, D. Jonkers, M.P. Weijenberg, J. Louwagie, C.W. Van, B. Carvalho, G.A. Meijer, S.B. Baylin, J.G. Herman, A.P. de Bruine, E.M. Van, GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 15, 3990–3997 (2009)PubMedCrossRef D.M. Hellebrekers, M.H. Lentjes, S.M. van den Bosch, V. Melotte, K.A. Wouters, K.L. Daenen, K.M. Smits, Y. Akiyama, Y. Yuasa, S. Sanduleanu, C.A. Khalid-de Bakker, D. Jonkers, M.P. Weijenberg, J. Louwagie, C.W. Van, B. Carvalho, G.A. Meijer, S.B. Baylin, J.G. Herman, A.P. de Bruine, E.M. Van, GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 15, 3990–3997 (2009)PubMedCrossRef
20.
Zurück zum Zitat M.S. Kim, J. Louwagie, B. Carvalho, J.S. Terhaar Sive Droste, H.L. Park, Y.K. Chae, K. Yamashita, J. Liu, K.L. Ostrow, S. Ling, R. Guerrero-Preston, S. Demokan, Z. Yalniz, N. Dalay, G.A. Meijer, C.W. Van, D. Sidransky, Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One 4, e6555 (2009)PubMedCrossRef M.S. Kim, J. Louwagie, B. Carvalho, J.S. Terhaar Sive Droste, H.L. Park, Y.K. Chae, K. Yamashita, J. Liu, K.L. Ostrow, S. Ling, R. Guerrero-Preston, S. Demokan, Z. Yalniz, N. Dalay, G.A. Meijer, C.W. Van, D. Sidransky, Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One 4, e6555 (2009)PubMedCrossRef
21.
Zurück zum Zitat M. Li, W.D. Chen, N. Papadopoulos, S.N. Goodman, N.C. Bjerregaard, S. Laurberg, B. Levin, H. Juhl, N. Arber, H. Moinova, K. Durkee, K. Schmidt, Y. He, F. Diehl, V.E. Velculescu, S. Zhou, L.A. Diaz Jr., K.W. Kinzler, S.D. Markowitz, B. Vogelstein, Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27, 858–863 (2009)PubMedCrossRef M. Li, W.D. Chen, N. Papadopoulos, S.N. Goodman, N.C. Bjerregaard, S. Laurberg, B. Levin, H. Juhl, N. Arber, H. Moinova, K. Durkee, K. Schmidt, Y. He, F. Diehl, V.E. Velculescu, S. Zhou, L.A. Diaz Jr., K.W. Kinzler, S.D. Markowitz, B. Vogelstein, Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27, 858–863 (2009)PubMedCrossRef
22.
Zurück zum Zitat B.M. Berger, D.A. Ahlquist, Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 44, 80–88 (2012)PubMedCrossRef B.M. Berger, D.A. Ahlquist, Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 44, 80–88 (2012)PubMedCrossRef
23.
Zurück zum Zitat F. Diehl, K. Schmidt, K.H. Durkee, K.J. Moore, S.N. Goodman, A.P. Shuber, K.W. Kinzler, and B. Vogelstein, Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients. Gastroenterology 135, 489–498 (2008) F. Diehl, K. Schmidt, K.H. Durkee, K.J. Moore, S.N. Goodman, A.P. Shuber, K.W. Kinzler, and B. Vogelstein, Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients. Gastroenterology 135, 489–498 (2008)
24.
Zurück zum Zitat D. Whitney, J. Skoletsky, K. Moore, K. Boynton, L. Kann, R. Brand, S. Syngal, M. Lawson, A. Shuber, Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn. 6, 386–395 (2004)PubMedCrossRef D. Whitney, J. Skoletsky, K. Moore, K. Boynton, L. Kann, R. Brand, S. Syngal, M. Lawson, A. Shuber, Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn. 6, 386–395 (2004)PubMedCrossRef
25.
Zurück zum Zitat H. Zou, H. Allawi, X. Cao, M. Domanico, J. Harrington, W.R. Taylor, T. Yab, D.A. Ahlquist, G. Lidgard, Quantification of methylated markers with a multiplex methylation-specific technology. Clin. Chem. 58, 375–383 (2012)PubMedCrossRef H. Zou, H. Allawi, X. Cao, M. Domanico, J. Harrington, W.R. Taylor, T. Yab, D.A. Ahlquist, G. Lidgard, Quantification of methylated markers with a multiplex methylation-specific technology. Clin. Chem. 58, 375–383 (2012)PubMedCrossRef
26.
Zurück zum Zitat C. Ostwald, M. Linnebacher, V. Weirich, F. Prall, Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int. J. Oncol. 35, 321–327 (2009)PubMed C. Ostwald, M. Linnebacher, V. Weirich, F. Prall, Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int. J. Oncol. 35, 321–327 (2009)PubMed
27.
Zurück zum Zitat D.A. Ahlquist, J.E. Skoletsky, K.A. Boynton, J.J. Harrington, D.W. Mahoney, W.E. Pierceall, S.N. Thibodeau, A.P. Shuber, Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219–1227 (2000)PubMedCrossRef D.A. Ahlquist, J.E. Skoletsky, K.A. Boynton, J.J. Harrington, D.W. Mahoney, W.E. Pierceall, S.N. Thibodeau, A.P. Shuber, Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219–1227 (2000)PubMedCrossRef
Metadaten
Titel
Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection
verfasst von
Linda J. W. Bosch
Sandra Mongera
Jochim S. Terhaar sive Droste
Frank A. Oort
Sietze T. van Turenhout
Maarten T. Penning
Joost Louwagie
Chris J. J. Mulder
Manon van Engeland
Beatriz Carvalho
Gerrit A. Meijer
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 4/2012
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0092-6

Weitere Artikel der Ausgabe 4/2012

Cellular Oncology 4/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …